Login
$AKTS
$16.16 -$0.46 (2.77%) Live

Who owns Aktis?

Institutions own, across all of Aktis's classes · 13F as of Q2 2026
61.2%
of the economics
63.3%
of the votes
Top 10 holders, by whole-company stake
Holder AKTS Economics Votes
MPM BIOIMPACT LLC 4.8M 8.67% 8.97%
EcoR1 Capital, LLC 4.8M 8.65% 8.95%

Sign up to see all 10.

Top 10 together 43.4% of the economics · 45.0% of the votes
By class
Class Shares outstanding Held by institutions Votes a share Economics a share
AKTS 53.9M 63.3% 1 vote 1
Class A 1.9M none filed no vote 1

SEC filing aktis_12.31.25_10k.htm: Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders provided, however, that, except as otherwise required by law, holders of common stock are not be entitled to vote on any amendment to the Company’s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of Preferred Stock if the hol...

SEC filing aktis_12.31.25_10k.htm: Our Class A common stock has no voting rights. As a result, all matters submitted to our stockholders will be decided by the vote of holders of our common stock. Based on the beneficial ownership of our common stock as of March 10, 2026, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 56.2% of our out...

How is ownership changing?

Institutions, last 8 quarters

A trend across this company's share classes isn't available yet: each quarter's 13F filings add up shares of classes that differ in economics and votes.

Biggest buyers in Q2 2026
  • Jupiter Topco LLC NEW +1.3M
  • TCG Crossover Management, LLC NEW +696.6K

Sign up to see all 5.

Biggest sellers in Q2 2026
  • Janus Henderson Group PLC SOLD OUT −1.5M
  • Price T Rowe Associates Inc /MD/ −800.7K

Sign up to see all 5.

Who is planning to sell?

Notices of proposed sale, last 12 months
$3.53M
5 notices from 4 people
Arranged in advance
16%
of the value is under a 10b5-1 plan
Under a 10b5-1 plan No plan
$0$1.5M$3.0MDecJanFebMarAprMayJunJul 2026: $3.0M without a planJulAugSep 2026: $552.8K under a 10b5-1 planSepOctNov
Largest proposed sellers
  • Akos Czibere Officer $1.39M
  • Shulamit Ron-Bigger Officer $1.39M

Sign up to see all 4.

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

There are not yet two fiscal years of reported share counts for Aktis Oncology, Inc..

How patient are the owners?

Institutional shares by how long they've been held
5+ years0% 3–5 years0% 1–3 years0% Under 1 year100%
Quarterly turnover
10.8%
of institutional shares changed hands
Top 10 managers, median time held
1 quarter

Super Investors

Investment managers reporting Aktis on Form 13F
MB
MPM Bioimpact LLC
Shares
4.8M
% of company
—
Change vs last qtr
Unchanged
Held since
Q1 '26
EC
EcoR1 Capital, LLC
13D · 9.1%
Shares
4.8M
% of company
—
Change vs last qtr
Unchanged
Held since
Q1 '26

28 more super investors behind a free account

See every manager holding Aktis Oncology, Inc., how their position has changed, and how long they've held it.

Sign up free

Institutional Funds

Mutual funds and ETFs reporting Aktis on Form N-PORT
VH
Vanguard Specialized Funds
Position value
$32.3M
% of company
—
% of the fund
0.08%
As of
July 31, 2026
TR
T. Rowe Price Small-Cap Stock Fund, Inc.
Position value
$21.8M
% of company
—
% of the fund
0.23%
As of
June 30, 2026

23 more funds behind a free account

See every fund holding Aktis Oncology, Inc. and how much of the fund the position is.

Sign up free

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G
AG
Ansbert Gadicke
5%+ holder13D · 19.3%
Shares
10.3M
% of company
—
Change vs last qtr
—
Held since
—
EL
Eli Lilly and Company
5%+ holder13D · 11.9%
Shares
6.3M
% of company
—
Change vs last qtr
—
Held since
—

20 more holders behind a free account

See every insider and 5%+ holder of Aktis Oncology, Inc..

Sign up free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support